NEWS & RESOURCES
First Treated Patient in First-In-Human Clinical Trial for Novel Brain Cancer Treatment
Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas,...
FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations
FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)
Alpheus Medical Announces Formation of World-Class Scientific Advisory Board
SAB to provide meaningful guidance as company begins first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas.
Alpheus Medical closes $16m in Series A financing for novel glioma brain cancer treatment
Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced it has closed $16M in Series A financing.
© 2021 Alpheus Medical Inc., All Rights Reserved. | CAUTION: Investigational device in the United States. Limited by Federal law to investigational use.